These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

424 related articles for article (PubMed ID: 32599878)

  • 1. Retrospective Study of Dupilumab Treatment for Moderate to Severe Atopic Dermatitis in Korea: Efficacy and Safety of Dupilumab in Real-World Practice.
    Jang DH; Heo SJ; Jung HJ; Park MY; Seo SJ; Ahn J
    J Clin Med; 2020 Jun; 9(6):. PubMed ID: 32599878
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A 52 weeks dupilumab treatment for moderate to severe atopic dermatitis in Korea: long-term efficacy and safety in real world.
    Jang DH; Heo SJ; Kook HD; Lee DH; Jung HJ; Park MY; Ahn J
    Sci Rep; 2021 Dec; 11(1):23539. PubMed ID: 34876623
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Clinical observation on the efficacy and safety of dupilumab in the treatment of moderate to severe atopic dermatitis].
    Li CY; Chen S; Qian WL; Yang L; Zheng Q; Chen AJ; Chen J; Huang K; Fang S; Wang P; Hu L; Liu XR; Zhao XQ; Tan N; Cai T
    Zhonghua Yu Fang Yi Xue Za Zhi; 2023 Oct; 57(10):1590-1595. PubMed ID: 37859375
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and Safety of Dupilumab in Chinese Patients With Atopic Dermatitis: A Real-World Study.
    Zhou B; Peng C; Li L; Liu R; Zhu L; Chen X; Li J
    Front Med (Lausanne); 2022; 9():838030. PubMed ID: 35402441
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A prospective observational cohort study comparing the treatment effectiveness and safety of ciclosporin, dupilumab and methotrexate in adult and paediatric patients with atopic dermatitis: results from the UK-Irish A-STAR register.
    Alexander H; Malek R; Prieto-Merino D; Gribaleva E; Baden M; Beattie P; Brown S; Burton T; Cameron S; Coker B; Cork MJ; Hearn R; Ingram JR; Irvine AD; Johnston GA; Lambert A; Lunt M; Man I; Newell L; Ogg G; Patel P; Wan M; Warren RB; Woolf R; Yiu ZZN; Reynolds N; Ardern-Jones MR; Flohr C
    Br J Dermatol; 2024 Nov; 191(6):988-999. PubMed ID: 39044673
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-World Effectiveness of Dupilumab in Adult and Adolescent Patients with Atopic Dermatitis: 2-Year Interim Data from the PROSE Registry.
    Simpson EL; Lockshin B; Lee LW; Chen Z; Daoud M; Korotzer A
    Dermatol Ther (Heidelb); 2024 Jan; 14(1):261-270. PubMed ID: 38175364
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Matching-Adjusted Indirect Comparison of the Efficacy at Week 32 of Tralokinumab and Dupilumab in the Treatment of Moderate-to-Severe Atopic Dermatitis.
    Torres T; Sohrt Petersen A; Ivens U; Bosch Vilaro A; Stinson J; Carrascosa JM
    Dermatol Ther (Heidelb); 2024 Apr; 14(4):983-992. PubMed ID: 38613642
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Response and Quality of Life in Patients with Severe Atopic Dermatitis Treated with Dupilumab: A Single-Center Real-Life Experience.
    Ferrucci S; Casazza G; Angileri L; Tavecchio S; Germiniasi F; Berti E; Marzano AV; Genovese G
    J Clin Med; 2020 Mar; 9(3):. PubMed ID: 32183179
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dupilumab treatment induced similar improvements in signs, symptoms, and quality of life in adults with moderate-to-severe atopic dermatitis with baseline Eczema Area and Severity Index Score <24 or ≥24.
    Offidani A; Stingeni L; Neri I; Cipriani F; Chen Z; Rossi AB; Lu Y; Moretti D
    Ital J Dermatol Venerol; 2022 Feb; 157(1):39-46. PubMed ID: 33878856
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of Dupilumab in 543 Adult Patients With Moderate-to-Severe Atopic Dermatitis: A Multicenter, Retrospective Study.
    Nettis E; Ferrucci SM; Ortoncelli M; Pellacani G; Foti C; Di Leo E; Patruno C; Rongioletti F; Argenziano G; Macchia L; Tavecchio S; Napolitano M; Ribero S; Bonzano L; Romita P; Di Bona D; Nisticò SP; Piras V; Calabrese G; Detoraki C; Carbonara M; Fabbrocini G
    J Investig Allergol Clin Immunol; 2022 Apr; 32(2):124-132. PubMed ID: 32856595
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of Long-Term Effectiveness and Safety of Upadacitinib for Atopic Dermatitis Between Dupilumab-Exposed and Dupilumab-Naïve Patients.
    Napolitano M; Ferrucci SM; Foggia L; Hansel K; Pezzolo E; Stingeni L; Antonelli E; Picone V; Patruno C
    Clin Drug Investig; 2024 Jan; 44(1):71-77. PubMed ID: 38105393
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Efficacy and safety of dupilumab in the treatment of moderate to severe atopic dermatitis].
    Wang JY; Zhou BJ; Cao QZ; Peng C; Chen ML; Chen X; Li J
    Zhonghua Yi Xue Za Zhi; 2024 Aug; 104(30):2810-2816. PubMed ID: 39085148
    [No Abstract]   [Full Text] [Related]  

  • 13. Real Clinical Practice Data of Monthly Dupilumab Therapy in Adult Patients With Moderate-to-Severe Atopic Dermatitis: Clinical Efficacy and Predictive Markers for a Favorable Clinical Response.
    Lee Y; Kim ME; Nahm DH
    Allergy Asthma Immunol Res; 2021 Sep; 13(5):733-745. PubMed ID: 34486258
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dupilumab Treatment Provides Sustained Improvements Over 2 Years in Symptoms and Quality of Life in Adults with Atopic Dermatitis.
    Yosipovitch G; de Bruin-Weller M; Armstrong A; Wu JJ; Herranz P; Thaçi D; Delevry D; Bagousse GB; Zhang R; Shumel B; Rossi AB; Chao J
    Dermatol Ther (Heidelb); 2021 Dec; 11(6):2147-2157. PubMed ID: 34714527
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dupilumab in daily practice for the treatment of pediatric atopic dermatitis: 28-week clinical and biomarker results from the BioDay registry.
    Kamphuis E; Boesjes CM; Loman L; Bakker DS; Poelhekken M; Zuithoff NPA; Kamsteeg M; Romeijn GLE; van Wijk F; de Bruin-Weller MS; de Graaf M; Schuttelaar MLA
    Pediatr Allergy Immunol; 2022 Dec; 33(12):e13887. PubMed ID: 36564878
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis and Prior Use of Systemic Non-Steroidal Immunosuppressants: Analysis of Four Phase 3 Trials.
    Griffiths C; de Bruin-Weller M; Deleuran M; Fargnoli MC; Staumont-Sallé D; Hong CH; Sánchez-Carazo J; Foley P; Seo SJ; Msihid J; Chen Z; Cyr SL; Rossi AB
    Dermatol Ther (Heidelb); 2021 Aug; 11(4):1357-1372. PubMed ID: 34142350
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The ability of biomarkers to assess the severity of atopic dermatitis.
    Nakahara T; Onozuka D; Nunomura S; Saeki H; Takenaka M; Matsumoto M; Kataoka Y; Fujimoto R; Kaneko S; Morita E; Tanaka A; Saito R; Okano T; Miyagaki T; Aoki N; Nakajima K; Ichiyama S; Kido-Nakahara M; Tonomura K; Nakagawa Y; Tamagawa-Mineoka R; Masuda K; Takeichi T; Akiyama M; Ishiuji Y; Katsuta M; Kinoshita Y; Tateishi C; Yamamoto A; Morita A; Matsuda-Hirose H; Hatano Y; Kawasaki H; Fukushima-Nomura A; Ohtsuki M; Kamiya K; Kabata Y; Abe R; Mitsui H; Kawamura T; Tsuji G; Katoh N; Furue M; Izuhara K
    J Allergy Clin Immunol Glob; 2024 Feb; 3(1):100175. PubMed ID: 37915726
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term Effectiveness and Safety of Upadacitinib for Atopic Dermatitis in a Real-world Setting: An Interim Analysis Through 48 Weeks of Observation.
    Chiricozzi A; Ortoncelli M; Schena D; Gori N; Ferrucci SM; Babino G; Napolitano M; Fargnoli MC; Stingeni L; Rossi M; Romanelli M; Balestri R; Pellegrino M; Parodi A; Bertoldi AM; Palazzo G; Antonelli F; Pitino A; Tripepi G; Fabbrocini G; Balato A; Marzano AV; Girolomoni G; Ribero S; Peris K
    Am J Clin Dermatol; 2023 Nov; 24(6):953-961. PubMed ID: 37322324
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dupilumab provides important clinical benefits to patients with atopic dermatitis who do not achieve clear or almost clear skin according to the Investigator's Global Assessment: a pooled analysis of data from two phase III trials.
    Silverberg JI; Simpson EL; Ardeleanu M; Thaçi D; Barbarot S; Bagel J; Chen Z; Eckert L; Chao J; Korotzer A; Rizova E; Rossi AB; Lu Y; Graham NMH; Hultsch T; Pirozzi G; Akinlade B
    Br J Dermatol; 2019 Jul; 181(1):80-87. PubMed ID: 30791102
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of atopic dermatitis with dupilumab: experience from a tertiary referral centre.
    Olesen CM; Holm JG; Nørreslet LB; Serup JV; Thomsen SF; Agner T
    J Eur Acad Dermatol Venereol; 2019 Aug; 33(8):1562-1568. PubMed ID: 30959559
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.